Low Incidence of Cardiac Events in Statin-Administered Patients in CAG Study

Abstract

Aim:The effect of statins in preventing cardiac events in Japanese coronary artery disease (CAD) patients was studied in a retrospective investigation of 148 patients diagnosed with CAD by coronary angiography (CAG). Methods: Sixty-five patients received statins within 2 weeks after CAG, and 83 patients did not receive statins after CAG. Results: In the statin group, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were reduced significantly with statin administration (p 0.01). In the non-statin group, baseline levels of TC, LDL-C and high-density lipoprotein cholesterol were not changed significantly at the end of the follow-up period. As for the effect of statin in preventing cardiac events, the incidence of cardiac events was significantly lower (p 0.0003) in the statin group (n 5: 8%) than in the nonstatin group (n 28: 34%). In subanalysis of 37 patients whose TC at the time of initial CAG was less than 200 mg/dL, none of the statin group (n 17) suffered a cardiac event. This was significantly lower than the incidence of cardiac events in the non-statin group (n 5: 25%; p 0.05). Conclusion:The present study demonstrated that lowering LDL-C of Japanese CAD patients by statin administration is effective to prevent cardiac events, particularly, a second percutaneous coronary intervention (PCI) for restenosis of a coronary artery following the initial PCI whether or not these patients had hypercholesterolemia.

The Relationship Between Low-Density Lipoprotein Cholesterol Levels and the Incidence of Cardiovascular Disease in High-Risk Patients Treated With Pravastatin

“…[18][19][20][21] Of these studies, the landmark MEGA Study clearly revealed that pravastatin significantly reduces cardiovascular disease by 30%, with an 18% decrease in LDL-C in patients without a history of cardiovascular disease, 18) and various fi ndings of the MEGA Study have been cited in the current JAS guideline. 15) However, exactly how pravastatin works in high-risk patients in primary prevention categorized by the JAS guideline has not been well investigated to date.…”

Atorvastatin does not Affect Ischaemia-Induced Phosphatidylserine Exposition in Humans in-vivo

“…The cholesterol lowering action of statins (HMG-coenzyme A reductase inhibitors) and its associated reduction in cardiovascular events have been well documented in numerous clinical trials [1][2][3][4] . Traditionally, this beneficial effect of statins has been explained by lowering of plasma cholesterol and sub-sequent reduced progression of atherosclerosis.…”

Seasonal Variation in Serum Lipid Levels in Japanese Workers

“…It is clear that elevated levels of LDL cholesterol are a major predictor of cardiovascular disease (CVD). In addition, a number of large randomized controlled trials have demonstrated that LDL cholesterol lowering with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy can substantially reduce CVD-related morbidity and mortality [2][3][4][5] . Thus, recent treatment guidelines, such as the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP ), have been proposed for LDL cholesterol levels based on the number of risk factors 6) ; however, the guidelines do not take into consideation that seasonal variation in serum LDL cholesterol levels may affect clinical management.…”